BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37085602)

  • 21. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
    Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
    BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
    Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.
    Baumgarten SC; Frasor J
    Mol Endocrinol; 2012 Mar; 26(3):360-71. PubMed ID: 22301780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468.
    Natarajan S; Ranganathan M
    Immunopharmacol Immunotoxicol; 2020 Oct; 42(5):408-415. PubMed ID: 32686546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells.
    Chen X; Ma N; Zhou Z; Wang Z; Hu Q; Luo J; Mei X; Yang Z; Zhang L; Wang X; Feng Y; Yu X; Ma J; Guo X
    Med Sci Monit; 2017 Jun; 23():2674-2683. PubMed ID: 28570501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma.
    Banerjee A; Wu ZS; Qian P; Kang J; Pandey V; Liu DX; Zhu T; Lobie PE
    Breast Cancer Res; 2011; 13(6):R112. PubMed ID: 22060274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
    Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
    Breast J; 2022; 2022():9238804. PubMed ID: 35711896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
    Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
    Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer.
    Murthy SRK; Cheng X; Zhuang T; Ly L; Jones O; Basadonna G; Keidar M; Canady J
    Sci Rep; 2022 Mar; 12(1):4038. PubMed ID: 35260587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
    Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
    PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
    Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
    Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
    Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype.
    Christgen M; Geffers R; Kreipe H; Lehmann U
    Cancer Sci; 2013 Dec; 104(12):1726-30. PubMed ID: 24344720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
    Bhat R; Thangavel H; Abdulkareem NM; Vasaikar S; De Angelis C; Bae L; Cataldo ML; Nanda S; Fu X; Zhang B; Schiff R; Trivedi MV
    Sci Rep; 2022 Feb; 12(1):1972. PubMed ID: 35121782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Zhang L; Yu Q; Wu XC; Hsieh MC; Loch M; Chen VW; Fontham E; Ferguson T
    Breast Cancer Res Treat; 2018 May; 169(1):175-187. PubMed ID: 29368311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
    Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
    Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol.
    Girgert R; Emons G; Gründker C
    BMC Cancer; 2014 Dec; 14():935. PubMed ID: 25496649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.